Skip to content
10-Q

Quarterly Report

Nuvectis Pharma, Inc. NVCT

0001558370-25-006497

← back to feed
Filed
May 6, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 1, 2025 23.63M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $29.86M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $18.53M
Current Liabilities Q1 2025 · Mar 31, 2025 $9.19M
Current Liabilities Q1 2025 · Dec 31, 2024 $8.89M
Total Liabilities Q1 2025 · Mar 31, 2025 $9.19M
Total Liabilities Q1 2025 · Dec 31, 2024 $8.89M
Current Assets Q1 2025 · Mar 31, 2025 $30.15M
Current Assets Q1 2025 · Dec 31, 2024 $18.61M
Total Assets Q1 2025 · Mar 31, 2025 $30.15M
Total Assets Q1 2025 · Dec 31, 2024 $18.61M
Shares Diluted Q1 2025 · Mar 31, 2024 16.56M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$4.36M
Stockholders Equity Q1 2025 · Mar 31, 2024 $14.02M
Stockholders Equity Q1 2025 · Dec 31, 2023 $12.2M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.25
Eps Basic Q1 2025 · Mar 31, 2024 −$0.25
Sga Expense Q1 2025 · Mar 31, 2024 $1.74M
Rd Expense Q1 2025 · Mar 31, 2024 $2.66M
Net Income Q1 2025 · Mar 31, 2024 −$4.17M
Operating Income Q1 2025 · Mar 31, 2024 −$4.4M